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Abstract
A mechanism used by cells to regulate their volume under
hypo-osmotic conditions is the release of organic osmolytes,
one of which is myo-inositol. The possibility that activation of
phospholipase-C-linked receptors can regulate this process
has been examined for SH-SY5Y neuroblastoma cells. Incu-
bation of cells with hypo-osmolar buffers (160–250 mOsm) led
to a biphasic release of inositol which persisted for up to 4 h
and could be inhibited by inclusion of anion channel blockers –
results which indicate the involvement of a volume-sensitive
organic anion channel. Inclusion of oxotremorine-M, a mu-
scarinic cholinergic agonist, resulted in a marked increase
(80–100%) in inositol efflux under hypo-osmotic, but not iso-
tonic, conditions. This enhanced release, which was observed
under all conditions of hypo-osmolarity tested, could be
prevented by inclusion of atropine. Incubation of the cells with
either the calcium ionophore, ionomycin, or the phorbol ester,
phorbol 12-myristate 13-acetate, partially mimicked the stim-
ulatory effect of muscarinic receptor activation when added
singly, and fully when added together. The ability of
oxotremorine-M to facilitate inositol release was inhibited by
removal of extracellular calcium, depletion of intracellular
calcium or down-regulation of protein kinase C. These results
indicate that activation of muscarinic cholinergic receptors can
regulate osmolyte release in this cell line.
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Regulation of cell volume is essential for many physiological
processes and is of prime importance to the CNS, because of
the restricted volume of the skull. Brain cells can swell in
response to either changes in plasma osmolarity (hypo-
osmotic swelling) or from changes in intracellular ion and
water distribution (isotonic swelling). The latter is also
referred to as cellular or cytotoxic edema (Kimelberg 2000;
Pasantes-Morales et al. 2000). Hypo-osmotic swelling fre-
quently occurs as a result of hyponatremia, which is
associated with clinical conditions such as congestive heart
failure, nephrotic syndrome and hepatic cirrhosis. Water
overload may also occur in some psychiatric disorders, such
as schizophrenia, or in athletes and in instances of the
inappropriate secretion of anti-diuretic hormone. The major-
ity of symptoms observed are neurological and include
disorientation, mental confusion and seizures.
In response to hypo-osmotic stress, neural cells swell, and
to restore osmotic balance a loss of K+ and Cl– ions is
initially observed. However, as large changes in ion
concentrations can adversely impact cell excitability,
cells subsequently utilize ‘compatible’ or ‘non-perturbing’
osmolytes which are specifically designed to counter changes
in osmolarity without compromising cell function. Three
distinct classes of osmolytes can be identified, namely (i)
amino acids, such as glutamate or taurine, (ii) methylamines,
such as betaine and glycerophosphorylcholine, and (iii)
polyols, such as myo-inositol or sorbitol. Of these, inositol,
glutamate and taurine represent the quantitatively major
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osmolytes in the brain. Although cells may utilize a number
of different transport systems for cell volume regulation (see
Lang et al. 1998), organic osmolytes are released from
neural cells via a ‘volume-sensitive organic anion channel’
(VSOAC). This channel, which has been extensively char-
acterized both electrophysiologically and pharmacologically,
is selectively permeable to anions (primarily Cl–) and organic
osmolytes, but not to cations (see Nilius et al. 1997; Lang
et al. 1998; for reviews). The loss of these osmolytes, along
with the attendant efflux of intracellular water, restores
osmotic balance and effects a regulatory volume decrease
(RVD) in the cell (McManus et al. 1995).
Evidence that inositol can function as a physiologically
important osmolyte was first obtained from experiments in
which animals were rendered either hyper- or hyponatremic.
Hypernatremia results in a significant increase in inositol
concentration (65–200%) within the brains of either experi-
mental animals (Lien et al. 1990; Löhr et al. 1998) or
humans (Lee et al. 1994). Conversely, a loss of inositol (40–
90%) from the brains of mice, rats or humans is observed
under conditions of hyponatremia (Thurston et al. 1989;
Lien et al. 1991; Haussinger et al. 1994; Videen et al. 1995).
Of the relatively few in vitro studies that have addressed the
mechanism of inositol release from neural cells, nearly all
have been restricted to astrocytes or glial tumor cells. In the
latter, cell swelling has been shown to rapidly activate a Na+-
independent, passive, low-affinity inositol efflux mechanism
(Jackson and Strange 1993), which can be blocked by the
inclusion of inhibitors of anion channels such as DIDS or
NPPB – a pharmacological profile consistent with the
involvement of VSOAC (Strange et al. 1993). Although it
has been assumed that inositol efflux occurs primarily from
glia, recent data from this laboratory indicate that high
concentrations of inositol can also be observed in some
neuronal populations, e.g. NT2-N neurons (Novak et al.
1999; for review see Fisher et al. 2002). Moreover, we have
recently demonstrated that hypotonicity activates the release
of myo-inositol from differentiated NT2-N neurons with a
pharmacological inhibition profile consistent with the pres-
ence of VSOAC on these cells (Novak et al. 2000). Taken
collectively, these results suggest that both neurons and glia
may utilize inositol efflux to regulate their cell volume.
Although a number of cell signaling pathways have been
implicated in cell volume regulation (see Nilius et al. 1997;
Lang et al. 1998; Pasantes-Morales et al. 2000; for reviews),
the most consistent observation to date is that a tyrosine
kinase appears to be required for activation of VSOAC in
response to cell swelling (Crepel et al. 1998; Mongin et al.
1999; Deleuze et al. 2000; Morales-Mulia et al. 2001). Little
is known, however, about whether osmolyte release, once
initiated, is subject to neurohumoral regulation. In this
regard, the ability of Ca2+ ionophores and phorbol esters to
enhance osmolyte efflux in C6 glioma cells and NT2-N
neurons (Strange et al. 1993; Novak et al. 2000) could
indicate a regulatory role for phospholipase C (PLC)-linked
receptors. Given that the CNS possesses a large number of
PLC-linked receptors (Fisher et al. 1992) and the importance
of cell volume regulation to brain function, this issue
assumes major physiological significance.
In this study, we demonstrate that human SH-SY5Y
neuroblastoma cells, which possess high concentrations of
inositol (Novak et al. 1999), release the polyol upon hypo-
osmotic challenge. Moreover, this release is significantly
enhanced following agonist occupancy of muscarinic cho-
linergic receptors (mAChRs), which results in the activation
of PLC. This stimulation of inositol efflux appears to be
mediated, at least in part, via a rise in cytoplasmic Ca2+
(Ca2+i) concentrations and activation of PKC. A preliminary
account of part of this study has previously been reported
(Fisher et al. 2003).
Materials and methods
Materials
myo-[2–3H]Inositol (80 Ci/mmol) and [1,2–3H]taurine (32 Ci/
mmol) were obtained from Amersham Corp. (Arlington Heights,
IL, USA). Phorbol 12-myristate 13-acetate (PMA), 4a-phorbol
12,13-didecanoate, all trans-retinoic acid, 4,4¢diisothiocyanato-
stilbene-2,2¢-disulfonic acid (DIDS), 3-[4-hydroxyphenyl]-1-[2,4,
6-trihydroxyphenyl]-1-propanone (phloretin), 1-[p-dimethyl-amino-
ethoxyphenyl]-1,2-diphenyl 1-butene (tamoxifen), 5-nitro-2-(3-phe-
nylpropylamino) benzoic acid (NPPB), 2-butyn-1-ammonium
N,N,N-trimethyl-4-(2-oxo-1-pyrrolidinyl) iodide (oxotremorine-M;
Oxo-M), atropine and pilocarpine were obtained from Sigma
Chemical Co. (St. Louis, MO, USA). Thapsigargin, ionomycin
and bisindolylmaleimide (BIM) were obtained from Calbiochem
(San Diego, CA, USA). Dulbecco’s modified Eagle’s medium
(DMEM), 50 · penicillin/streptomycin (5000 U/mL of penicillin G
sodium and 5000 lg/mL of streptomycin sulfate) were obtained
from Gibco (Grand Island, NY, USA). Fetal calf serum was from
BioWhittaker (Walkersville, MD, USA). Tissue culture supplies
were obtained from Corning Glass Works (Corning, NY, USA),
Sarstedt (Newton, NC, USA) and Becton-Dickinson (Franklin
Lakes, NJ, USA). Universol liquid scintillation cocktail was from
ICN (Costa Mesa, CA, USA). Dowex-1 resin (100–200 mesh; · 8
formate) was obtained from Bio-Rad Laboratories (Hercules, CA,




SH-SY5Y cells (passages 69–93) were grown in tissue culture flasks
(75 cm2/250 mL) in 20 mL of DMEM supplemented with 10%
(v/v) of fetal calf serum. Cells were grown for 3–10 days at 37C in
a humidified atmosphere containing 10% CO2. Cells were isolated
after aspiration of the medium and incubation with a modified
Puck’s D1 solution (Honneger and Richelson 1976). Cells were then
resuspended in DMEM/10% fetal calf serum and subcultured into
35 mm, 6-well culture plates for 2–4 days. Experiments were
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routinely conducted on cells that had reached 50–90% confluency.
In some experiments, SH-SY5Y cells were differentiated into the
neuronal phenotype following a 6-day incubation in the presence of
10 lM retinoic acid (Rosner et al. 1995).
Efflux of inositol or taurine
Osmolyte efflux from SH-SY5Y neuroblastoma cells was monit-
ored essentially as previously described (Novak et al. 1999, 2000).
Cells grown in 6-well plates were allowed to pre-label at 37C for
24–48 h in the presence of 2–3 lCi/mL of myo-[2–3H]inositol or
for 3 h in the presence of 1 lCi/mL of [1,2–3H]taurine. After pre-
labeling, the medium was aspirated and cells washed with
2 · 2 mL of isotonic buffer A (142 mM NaCl, 5.6 mM KCl,
2.2 mM CaCl2, 3.6 mM NaHCO3, 1 mM MgCl2 and 30 mM
HEPES, pH 7.4). Cells were then allowed to incubate in 2 mL
of either isotonic buffer A (approx. 300 mOsm) or hypotonic
buffer A (150–275 mOsm; rendered hypotonic by the reduction in
NaCl concentration). Osmolarities of buffer A were monitored by
means of an Osmette precision osmometer (PS Precision Systems,
Sudbury, MA, USA). At the times indicated, aliquots (50–200 lL)
of the extracellular medium were removed and radioactivity
determined after the addition of 5 mL of Universol scintillation
fluid. In some experiments, the extracellular medium was
centrifuged at 7800 g for 2 min (to account for any cell debris)
and the release of radioactivity compared with that observed for
non-centrifuged samples. Values for radioactivity released were
comparable using the two procedures. To terminate the reactions,
the medium was rapidly aspirated and the cells lysed with
2 · 1 mL of ice-cold 6% (wt/vol) trichloroacetic acid and water-
soluble radioactivity determined, as previously described. Total
water-soluble radioactivity present initially in the cells was
calculated as the sum of that recovered in the extracellular
medium and that remaining in the lysate at the end of the assay.
Efflux of either inositol or taurine at any given time was then
routinely expressed as the ratio of radioactivity present in the
extracellular medium to total soluble radioactivity (as a percent-
age). In experiments in which a treatment resulted in statistically
significant changes in the basal efflux of inositol (which is defined
as the release of inositol under hypo-osmotic conditions), results
for Oxo-M-stimulated efflux were expressed as an increase over
basal (see Fig. 8). In experiments in which cells were pre-labeled
with 3H-inositol, more than 99% of the radioactivity released from
cells co-eluted with myo-inositol, as determined by anion-
exchange chromatography (Fisher et al. 1984).
Phosphoinositide turnover
To monitor phosphoinositide turnover, SH-SY5Y cells that had been
pre-labeled with 3H-inositol were incubated in hypotonic buffer A
that contained 5 mM LiCl. The accumulation of radiolabeled inositol
phosphates present in the trichloroacetic acid cell lysates was
determined as previously described (Thompson and Fisher 1990).
Data analysis
Values quoted are means ± SEM for the numbers of independent
experiments indicated. Student’s two-tailed t-tests were used to
evaluate the statistical differences of the means of unpaired or paired
sets of data.
Results
Hypo-osmolarity elicits an increased efflux of inositol
from SH-SY5Y cells
When SH-SY5Y cells that had been allowed to pre-label with
3H-inositol were exposed to hypotonic buffer A, there was an
enhancement of inositol efflux (171, 722 and 2420% of
isotonic control at 251, 200 and 157 mOsm after a 20-min
incubation, respectively; Fig. 1). In contrast, little or no
efflux of inositol could be detected under iso-osmotic
conditions (316 mOsm). At osmolarities of 200 and 157
mOsm, inositol efflux was clearly biphasic, with an initial
rapid rate of release which lasted for approximately 5–
10 min, followed by a slower, but sustained, release of
inositol which persisted for up to 4 h. Unless indicated
otherwise, in subsequent experiments, an osmolarity of
approximately 160 mOsm was routinely employed and
efflux monitored at either 10- or 20-min time points.
Inositol efflux is inhibited by anion channel blockers
The release of inositol that occurred under conditions of
hypo-osmolarity could be substantially inhibited by agents
known to block anion channels (such as VSOAC). Thus, at
concentrations of 10–300 lM, inclusion of either DIDS,
NPPB or phloretin inhibited inositol efflux by up to 60–70%
(Fig. 2). Higher concentrations of these agents could not be
tested as they resulted in detachment of the cells from the
dish. Inclusion of tamoxifen, another agent purported to
Fig. 1 Hypo-osmolarity enhances inositol efflux from SH-SY5Y neur-
oblastoma. Cells that had been pre-labeled overnight in the presence
of 3H-inositol (3 lCi/mL) were washed twice with 2 mL of isotonic
buffer A prior to incubation in buffer A at the osmolarities shown.
Reactions were terminated at the times indicated and inositol efflux
monitored. Results are expressed as inositol efflux (per cent of total
soluble radioactivity at time zero) and are the means of three repli-
cates ± SEM. When not shown, SEM values fell within the symbol.
Data shown are from one of three experiments that gave similar
results.
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block VSOAC in some, but not all, tissues at relatively low
concentrations, had only a minimal effect on inositol release
(11 ± 10% inhibition at 30 lM, n ¼ 3).
mAChR activation regulates inositol efflux
under hypo-osmotic conditions
When SH-SY5Y cells were incubated in hypotonic buffer A
(160 mOsm), the addition of 1 mM Oxo-M resulted in a
marked stimulation of inositol efflux at all times examined
(Fig. 3a). In contrast, Oxo-M addition did not result in an
enhanced efflux of inositol under isotonic conditions.
Inclusion of atropine (10 lM) could fully block the stimu-
latory effect of Oxo-M, while having no effect on efflux on
its own (Fig. 3b). Inclusion of 200 lM DIDS resulted in a
44 ± 8% inhibition of Oxo-M-stimulated inositol efflux
(n ¼ 3), indicating the involvement of a VSOAC. The
presence of 1 mM Oxo-M was observed to consistently
enhance inositol efflux under hypo-osmotic conditions
(195 ± 8% of control at a 10-min time point, n ¼ 35).
Addition of the partial agonist, pilocarpine (1 mM), elicited a
correspondingly smaller increase in inositol efflux
(122 ± 10% of control vs. 184 ± 20% for Oxo-M in the
same experiments, n ¼ 3). When SH-SY5Y cells were pre-
incubated with 1 mM Oxo-M for 24 h (conditions under
which mAChRs undergo internalization and down-regula-
tion, see Sorensen et al. 1999), these cells were found to be
much less responsive to the subsequent addition of Oxo-M
under hypo-osmotic conditions (112 ± 9% of control vs.
189 ± 5% of control for untreated cells, n ¼ 3). Although
undifferentiated (rapidly dividing) cells were routinely used
for the present studies, we also wanted to determine whether
the agonist stimulation of inositol efflux could be observed in
post-mitotic cells. The latter cell type would more closely
resemble that present in the CNS. When SH-SY5Y cells
were pre-treated with 10 lM retinoic acid for 6 days to effect
their differentiation into the neuronal phenotype (Rosner
et al. 1995), the addition of Oxo-M enhanced the efflux of
inositol to 180 ± 14% of control, whereas the corresponding
Fig. 2 Anion channel blockers inhibit inositol efflux under conditions of
hypotonicity. Cells that had been pre-labeled with 3H-inositol for 24 h
were washed twice with isotonic buffer A and incubated in hypotonic
buffer A (160 mOsm) in the presence or absence of DIDS, NPPB or
phloretin at the concentrations indicated. After a 20-min incubation,
reactions were terminated and inositol efflux monitored. Results are
expressed as inhibition of inositol efflux relative to untreated hypotonic
control. Data shown are means ± SEM for four independent experi-
ments, each performed in triplicate.
Fig. 3 Agonist occupancy of mAChRs facilitates the release of inositol
from SH-SY5Y neuroblastoma. (a) Cells pre-labeled with 3H-inositol
were washed with isotonic buffer A and incubated in either hypotonic
(Hypo: 160 mOsm) or isotonic (Iso: 310 mOsm) buffer A for the times
indicated in the presence or absence of 1 mM Oxo-M and inositol efflux
monitored. Results shown are expressed as inositol efflux (per cent of
total radioactivity) and are the means ± SEM for triplicate replicates.
Data shown are from one of three experiments that gave similar
results. (b) Cells were incubated in hypotonic buffer A (160 mOsm) in
the absence or presence of 1 mM Oxo-M, 10 lM atropine (Atr) or both
reagents. Reactions were terminated after 20 min and inositol efflux
monitored. Results shown are means ± SEM for five to six inde-
pendent experiments, each performed in triplicate. *Different from
hypotonic control, p < 0.002; **different from Oxo-M alone, p < 0.001.
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value for undifferentiated cells was 202 ± 29% (n ¼ 3).
Values for the release of inositol under basal conditions
(minus Oxo-M) were also similar (9.0 and 7.8% of total
soluble radioactivity for undifferentiated and differentiated
cells, respectively, after a 20-min incubation).
The ability of Oxo-M to stimulate inositol efflux could be
observed at time points as early as 1 min, and in the presence
of the agonist, inositol release was clearly biphasic, with the
rate of inositol efflux declining after the first 5 min of
incubation, as observed for control cells (Fig. 4a). If
SH-SY5Y cells were first exposed to hypotonic buffer A
for 20 min and then Oxo-M added (i.e. after the initial rapid
phase of inositol efflux), a significant stimulation of inositol
release was still observed (Fig. 4b). The EC50 value for Oxo-
M-mediated stimulation of inositol efflux was 1.5 lM, a
value similar to that observed for mAChR-mediated stimu-
lation of inositol phosphate formation (EC50 ¼ 4.0 lM;
Fig. 5).
mAChR activation stimulates the release of either
inositol or taurine under conditions of mild
hypo-osmolarity
The ability of Oxo-M to enhance the release of inositol under
conditions of pronounced hypo-osmolarity (160 mOsm)
could also be observed when the cells were exposed to
smaller reductions in osmolarity. When the osmolarity of
buffer A was reduced to 250 or 227 mOsm, inositol release
was increased (131 and 177% of control vs. isotonic,
respectively). Inositol release was further enhanced by
inclusion of Oxo-M (152 and 191% of control at 250 and
227 mOsm, respectively). In contrast, no effect of the agonist
on inositol release could be observed when cells were
incubated in isotonic buffer A (Fig. 6a). We also examined
the ability of mAChR activation to facilitate the release of
taurine, an amino acid that is well documented to serve as an
Fig. 4 Kinetics of Oxo-M-stimulated inositol efflux. (a) SH-SY5Y cells
that had been pre-labeled with 3H-inositol for 24 h were first washed in
isotonic buffer A and then incubated in hypotonic buffer A
(159 mOsm) in the presence or absence of 1 mM Oxo-M (added at
time zero, as indicated by the arrow). Reactions were terminated at the
times indicated and inositol efflux monitored. Values shown are the
means ± SEM for triplicate replicates. Results shown are from one of
two experiments that gave similar results. (b) Cells were treated as
described in (a), with the exception that cells were allowed to incubate
for 20 min in hypotonic buffer A prior to the addition of Oxo-M (indi-
cated by arrow). Values shown are means ± SEM for triplicate repli-
cates.
Fig. 5 Dose–response relationship for Oxo-M-stimulated inositol
efflux or inositol phosphate accumulation. Cells that had been pre-
labeled with 3H-inositol were washed in isotonic buffer A and incuba-
ted in the presence of hypotonic buffer A (160 mOsm) that contained
5 mM LiCl. Reactions were terminated after 20 min and inositol efflux
monitored. The accumulation of radiolabeled inositol phosphates in
the trichloroacetic acid cell lysates was monitored as an index of sti-
mulated phosphoinositide turnover. Results are expressed as a per
cent of the maximum response (obtained at 1 mM Oxo-M) and are
based upon measurement of triplicate replicates at each agonist
concentration. The calculated EC50 values were 1.5 lM for inositol
efflux and 4.0 lM for inositol phosphate accumulation. In a second
experiment, values of 0.4 and 1.4 lM were obtained for the two
responses, respectively.
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osmolyte in neural cells (Pasantes-Morales et al. 2000).
Under conditions of mild hypo-osmolarity (275–
227 mOsm), taurine was readily released from SH-SY5Y
neuroblastoma cells (273–532% of control vs. isotonic).
mAChR activation resulted in a marked enhancement of
taurine release under all conditions of hypo-osmolarity, but
not when the cells were incubated in isotonic buffer A
(Fig. 6b).
Inositol efflux can be enhanced following activation of
protein kinase C (PKC) or a rise in intracellular Ca2+
When SH-SY5Y cells were incubated in hypotonic buffer A
(160 mOsm), the addition of either 100 nM PMA, a PKC
agonist, or 1 lM ionomycin (an agent that elevates Ca2+i
concentrations; see Fisher et al. 1989) significantly increased
inositol efflux (139 ± 5 or 144 ± 4% of control, respectively,
n ¼ 6). In contrast, the inactive phorbol ester, 4a-phorbol
was without effect (103 ± 4% of control; Fig. 7). Neither
PMA nor ionomycin could facilitate inositol release when the
cells were incubated under isotonic conditions. When both
PMA and ionomycin were added to hypotonically treated
cells, their effect on inositol release was additive (192 ± 13%
of control), and efflux was comparable with that observed in
the presence of Oxo-M (200 ± 19% of control).
mAChR-mediated stimulation of inositol efflux
is mediated by both protein kinase C and Ca2+
Although both the activation of protein kinase C (by PMA)
and a rise in [Ca2+i] (elicited by ionomycin) can increase
inositol release, these observations do not, by themselves,
demonstrate that the effects of mAChR activation are
mediated by these mechanisms. To investigate the involve-
ment of PKC in the ability of mAChRs to stimulate inositol
efflux, two series of experiments were performed. In the first,
SH-SY5Y cells were allowed to pre-incubate overnight in the
presence of PMA – a condition that results in the down-
regulation of PKC activity (Cioffi and Fisher 1990). The
Fig. 6 Oxo-M can stimulate the efflux of either inositol or taurine under
conditions of mild hypo-osmolarity. Cells that had been pre-labeled in
the presence of either 3H-inositol (a) or 3H-taurine (b) were washed
with isotonic buffer A and incubated in buffer A at the osmolarities
indicated in the absence or presence of 1 mM Oxo-M. Experiments
were terminated after 20 min and inositol or taurine efflux monitored.
Results are expressed as inositol or taurine efflux (per cent of total
radioactivity) and are means ± SEM for five (inositol release) or six
(taurine release) independent experiments, each performed in tripli-
cate. (a) *Different from isotonic control, p < 0.02; **different from
hypotonic control (minus Oxo-M), p < 0.03. (b) *Different from isotonic
control, p < 0.02; **different from hypotonic control (minus Oxo-M),
p < 0.003.
Fig. 7 Activation of either PKC, or a rise in intracellular Ca2+ con-
centration, facilitates inositol efflux from SH-SY5Y neuroblastoma.
Cells that had been pre-labeled with 3H-inositol were washed with
isotonic buffer A and then incubated in hypotonic buffer A
(160 mOsm) in the presence or absence of 4-alpha phorbol
(4-aP,100 nM), PMA (100 nM), ionomycin (1 lM) or Oxo-M (1 mM).
Inositol efflux was monitored after a 20-min incubation. Results shown
are means ± SEM for four to five independent experiments, each
performed in triplicate. *Different from hypotonic control, p < 0.005;
**different from either PMA or ionomycin alone, p < 0.006.
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basal release of inositol under hypotonic conditions was
unimpaired in PKC down-regulated cells. In fact, a small
increase in inositol efflux was consistently observed after
PMA pre-treatment (127 ± 8% of control, n ¼ 10,
p < 0.002). However, following PKC down-regulation, the
ability of PMA to stimulate inositol efflux was abolished
while the ability of the agonist to enhance the release of the
polyol was reduced by 41–46% (Figs 8a and c). In a second
series of experiments, SH-SY5Y cells were pre-treated for
2 h with 3 lM BIM, a competitive antagonist of PKC
(Wilkinson et al. 1993), and then challenged with either
100 nM PMA or 1 mM Oxo-M. Pre-treatment of cells with
BIM resulted in a small increase in inositol efflux (110 ± 3%
of control, n ¼ 5, p < 0.03). Following pre-treatment with
BIM, the ability of PMA to stimulate inositol release was
substantially (although not completely) reduced, whereas
enhanced inositol efflux in response to Oxo-M addition was
only modestly impaired (16% inhibition; Fig. 8b). These
results, taken together with the PMA-pre-treatment data,
suggest that PKC activation plays a limited role in enhanced
inositol efflux following mAChR activation.
Omission of extracellular Ca2+ (nominally Ca2+-free
buffer A) resulted in a small and variable reduction in the
basal release of inositol under hypotonic conditions
()15 ± 7%, n ¼ 9, p < 0.05). However, the ability of
Oxo-M to enhance inositol efflux was substantially reduced
(50 ± 6%, n ¼ 9; Fig. 8c). Under the same conditions,
Oxo-M stimulation of inositol phosphate formation was
reduced by 49 ± 3% (n ¼ 4, p < 0.02). An additional
indication that influx of extracellular Ca2+ is required for
agonist-stimulated osmolyte release was obtained from
experiments in which the inclusion of 250 lM LaCl3, an
inhibitor of Ca2+ entry into cells (Pandol et al. 1987; Kwan
et al. 1990), resulted in an inhibition of Oxo-M-stimulated
Fig. 8 PMA- or Oxo-M stimulation of inositol efflux following PKC
down-regulation or inhibition. (a) SH-SY5Y cells were allowed to pre-
label with 3H-inositol for 48 h and then in the absence or presence of
100 nM PMA for a further 24 h. Cells (control or PMA-pre-treated)
were then washed with isotonic buffer A and incubated in hypotonic
buffer A (160 mOsm; basal conditions) in the presence or absence of
100 nM PMA or 1 mM Oxo-M. Reactions were terminated after 10 min
and inositol efflux monitored. Results are expressed as increase in
inositol efflux over corresponding control (no agent added) for either
PMA or Oxo-M for the number of independent experiments performed.
(b) Cells were treated as described in (a), with the exception that cells
were pre-incubated with 3 lM BIM for 2 h, in place of PMA-pre-treat-
ment. The basal release of inositol observed under hypotonic condi-
tions was 7.5 ± 1.0% of total soluble radioactivity in (a), while the
corresponding value in (b) was 11.7 ± 0.4%. *Different from control
cells, p < 0.004; **different from control cells, p < 0.05 (matched-pair
analysis). (c) SH-SY5Y cells were pre-labeled with 3H-inositol for 24 h.
Cells were then pre-treated with either PMA (100 nM) or vehicle for an
additional 24 h. Cells were then washed with isotonic buffer A and
incubated in hypotonic buffer A (160 mOsm) in the presence or
absence of added Ca2+. Inositol efflux was monitored following a
10-min incubation. Results are expressed as the percentage increase
in inositol release observed in the presence of 1 mM Oxo-M, relative to
the appropriate control, for the number of independent experiments
indicated. The basal release of inositol observed under hypotonic
conditions with Ca2+ present was 9.4 ± 7% of total soluble radioac-
tivity. *Different from untreated cells, p < 0.003; **different from
inositol release monitored in the presence of Ca2+, p < 0.002; ***dif-
ferent from inositol release monitored in PMA-pre-treated cells in the
presence of Ca2+, p < 0.02.
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inositol efflux (42 ± 5%, n ¼ 6, p < 0.004) when compared
with control cells (that were incubated in the presence of
2.2 mM Ca2+ alone). In contrast, the basal release of inositol
was unaffected by La3+. Inclusion of La3+ also inhibited the
mAChR-stimulation of inositol phosphate formation to a
similar extent (46 ± 2% inhibition, n ¼ 8, p < 0.0001, when
compared with control cells).
To determine whether the availability of intracellular Ca2+
plays a role in inositol efflux, cells were pre-incubated for
5 min in the presence of 1 lM thapsigargin, a treatment
previously demonstrated to deplete intracellular stores of
Ca2+ in these cells (Slowiejko et al. 1994). Depletion of
intracellular Ca2+ had no effect on the basal release of
inositol, but resulted in a reduction in Oxo-M-stimulated
inositol release when assayed under nominally Ca2+-free
conditions (166 ± 4 vs. 144 ± 6% of basal when monitored
in the absence or presence of thapsigargin pre-treatment,
respectively, n ¼ 5, p < 0.01).
To determine whether the Ca2+ requirement for inositol
release was related to the involvement of a Ca2+-activated
form of PKC, the ability of the agonist to enhance inositol
efflux was monitored for SH-SY5Y cells that had been pre-
treated overnight with PMA and then efflux measured in the
presence of nominally Ca2+-free buffer. Under these condi-
tions, a 73 ± 1% inhibition of inositol release was observed
when compared with control cells (2.2 mM Ca2+ added, no
PMA-pre-treatment; Fig. 8c). Because the inhibitory effects
of Ca2+ depletion and PKC down-regulation on inositol
efflux are less than additive, part of the Ca2+ requirement
may reflect the involvement of a Ca2+-dependent isoform of
PKC. Although Ca2+ entry into cells can also occur via a
phospholipase-A2-mediated mechanism involving arachido-
nate release (Shuttleworth and Thompson 1999), in addition
to the conventional PLC route, no effect of 10 lM isotetr-
andrine (a phospholipase A2 inhibitor; Akiba et al. 1992) on
the ability of Oxo-M to stimulate inositol efflux was
observed (177 ± 20 and 180 ± 14% of control for control
or isotetrandine-incubated cells, respectively, n ¼ 3).
Discussion
When subjected to hypo-osmotic stress, SH-SY5Y neurob-
lastoma rapidly release inositol in a time- and osmolarity-
dependent manner. The release of inositol is distinctly
biphasic with a rapid release occurring during the first
5–10 min of incubation, followed by a slower, but sustained
release thereafter. Similar kinetics have previously been
obtained for inositol release from bovine sarcolemmal
vesicles (Hale and Rubin 1995) and from cultured astrocytes
(Isaacks et al. 1999). The pharmacological profile of inhibi-
tion of inositol release from SH-SY5Y cells by anion
transport blockers is consistent with the involvement of
VSOAC. Thus, inositol efflux was inhibited by both DIDS
and NPPB, two inhibitors of volume-sensitive anion
channels (Nilius et al. 1997), as well as by phloretin, an
agent which inhibits these same channels, but not the Ca2+-
activated anion channel (Fan et al. 2001). A similar
pharmacological profile was obtained for inositol release
from C6 glioma cells (Strange et al. 1993) or NT2-N neurons
(Novak et al. 2000). In contrast, tamoxifen, which appears
able to discriminate between VSOACs present in different
tissues (Leaney et al. 1997; Nilius et al. 1997; Brès et al.
2000), was unable to significantly inhibit inositol efflux from
SH-SY5Y neuroblastoma. The basal release of inositol from
SH-SY5Y cells was also relatively unaffected by removal of
extracellular Ca2+, depletion of intracellular Ca2+ or down-
regulation of PKC – results which are consistent with those
previously obtained for inositol efflux from C6 glioma cells
(Strange et al. 1993). These results suggest that both
neuronal and glial preparations release inositol upon hypo-
osmotic stress as part of an adaptive mechanism to restore
their volume.
The principal finding to emanate from the present study is
that inositol efflux from SH-SY5Y neuroblastoma (either
undifferentiated or retinoic-acid-differentiated) can be signi-
ficantly enhanced following agonist occupancy of mAChRs.
The ability of Oxo-M to promote inositol efflux was
observed regardless of whether the agonist was added prior
to, or after, osmolyte release had been initiated (Fig. 4).
Inclusion of pilocarpine, a partial agonist at mAChRs
(Thompson and Fisher 1990; Slowiejko et al. 1994), resulted
in a significantly smaller stimulation of inositol efflux than
that observed for Oxo-M. Confirmation of an involvement of
mAChRs in the regulation of inositol efflux was obtained
from experiments in which atropine was shown to fully
prevent the ability of Oxo-M to promote inositol efflux.
Furthermore, a prolonged incubation of SH-SY5Y cells with
Oxo-M, a treatment which results in the internalization and
down-regulation of mAChRs (Sorensen et al. 1999), resulted
in a substantial attenuation of agonist-induced efflux.
mAChR–mediated enhancement of inositol release observed
under conditions of hypo-osmotic stress was inhibited by
inclusion of DIDS. Moreover, Oxo-M was unable to facilitate
inositol release under iso-osmotic conditions. Thus, a
prerequisite for agonist regulation of VSOAC opening is
activation of the latter by hypotonic stress. These results,
taken together, indicate the involvement of a volume-
sensitive channel (such as VSOAC) in inositol efflux
following mAChR activation.
Only a very limited amount of information exists regard-
ing the possibility that VSOAC, in either neural or non-
neural cells, can be regulated by extracellular agonists. In this
context, agonist occupancy of thrombin receptors in endot-
helial cells (Manolopoulos et al. 1997), endothelin receptors
in cardiac myocytes (Du and Sorota 2000) or nucleotide
receptors on epithelial cells (Tsumura et al. 1996), have been
reported to enhance volume-activated Cl– currents mediated
via VSOAC. In addition, ATP, operating via P2u and/or P2y
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receptors, can potently stimulate excitatory amino acid
release from hypotonically stressed astrocytes (Mongin and
Kimelberg 2002). However, in none of these examples have
the signaling pathways yet been systematically examined.
Although we and others have previously demonstrated that
the activation of mAChRs in SH-SY5Y cells is linked to a
number of downstream consequences, such as PLC activa-
tion and second-messenger generation, Ca2+ mobilization
from both intra- and extracellular compartments, activation
of PKC, small MW GTP-binding proteins, MAP kinase and
reorganization of the actin cytoskeleton (Lambert and
Nahorski 1990; Offermanns et al. 1993; Linseman et al.
1998, 2000), our present results suggest that agonist
stimulation of inositol efflux is mediated via a rise in
[Ca2+i] and, to a lesser extent, PKC activity. The evidence for
this is threefold. First, the ability of Oxo-M to enhance
inositol release can be mimicked in part by the addition of
either ionomycin, a calcium ionophore, or the PKC agonist,
PMA. In combination these agents elicited an increase in
inositol efflux that was comparable with that of the agonist.
Second, both extra- and intracellular pools of Ca2+ appear to
be required for agonist-stimulated inositol release. Thus,
mAChR-stimulated release of inositol was significantly
reduced (40–50%) when cells were incubated in either
nominally Ca2+-free buffer A, or alternatively, in regular
hypotonic buffer A (containing 2.2 mM Ca2+) in the presence
of La3+, an inhibitor of Ca2+ entry into cells (Pandol et al.
1987; Kwan et al. 1990). Both of these experimental
paradigms resulted in a similar degree of inhibition of
stimulated inositol phosphate formation. It has previously
been reported that mAChR stimulation of PLC activity and
inositol 1,4,5-trisphosphate formation (which is linked to
Ca2+ mobilization) are strongly inhibited by removal of
extracellular Ca2+ (Fisher et al. 1990; Lambert et al. 1991).
Agonist occupancy of mAChRs on these cells leads to a
continuous influx of extracellular Ca2+ and the subsequent
elevation of [Ca2+i] results in a sustained activation of PLC.
Conversely, when Ca2+ entry into the cells is prevented (e.g.
by omission of extracellular Ca2+ or the presence of calcium
channels blockers such as Ni2+ or La3+), mAChR stimulation
of PLC activity declines. The present data suggest a similar
requirement for the influx of extracellular Ca2+ in agonist-
stimulated inositol efflux. Although extracellular Ca2+
appears to play the predominant role, the availability of
intracellular Ca2+ also regulates stimulated inositol efflux, as
indicated by the reduction in the release of the polyol
following depletion of intracellular Ca2+ stores with thaps-
igargin. Third, a role for PKC can be inferred from the ability
of either PMA- or BIM-pre-treatment to attenuate inositol
efflux. However, it is evident that, even in the absence of
PKC activity, the muscarinic agonist retains an ability to
significantly enhance inositol efflux. Although the signal
transduction mechanism(s) underlying the basal efflux of
inositol in response to hypo-osmolarity is independent of
extra- or intracellular Ca2+ and PKC, it is evident that the
efflux mechanism can be regulated in a Ca2+- and PKC-
dependent manner following mAChR activation. Taken
collectively, the present results suggest a role (in part, at
least) for PLC activation in the regulation of inositol efflux
following mAChR activation. However, a direct proof of this
hypothesis remains to be established because of technical
difficulties encountered with the use of two putative inhib-
itors of PLC. Thus, when SH-SY5Y cells were exposed to
U-73122 (Bleasdale et al. 1990) for 10 or 20 min (standard
incubation time), cell rounding and detachment from the dish
were observed. Moreover, although an acute (5-min) expo-
sure of the cells to the aminosteroid avoided cell detachment,
under these conditions a significant inhibition (40–50%) of
both basal- and stimulated efflux were observed – a result
that points to a non-specific mode of inhibition of osmolyte
release by this agent. As an alternative approach, we
examined the ability of the aminoglycoside, neomycin, to
inhibit PLC activity (Cedazo-Mı́nguez et al. 2002). How-
ever, in our hands, this agent, in the concentration range of
0.5–5 mM had little or no effect on either stimulated PLC
activity or inositol efflux. Although a direct confirmation of a
role for PLC in osmolyte efflux has yet to be obtained, it
should be noted that our results, which implicate phosphoi-
nositide hydrolysis in the regulation of stimulated inositol
release, and by inference, cell volume regulation, are
consistent with a previous study in astrocytes in which
receptor-stimulated inositol lipid turnover was linked to RVD
(Bender et al. 1993).
Although routinely monitored under conditions of pro-
nounced hypo-osmotic stress (160 mOsm), increases in
inositol efflux from SH-SY5Y cells were also detected
following 15–20% reductions in osmolarity, i.e. 227–
250 mOsm, values similar to plasma osmolarities encoun-
tered during hyponatremia (Andrew 1991; Haussinger et al.
1994). Oxo-M could significantly increase inositol efflux
under conditions of hypo-osmolarity in which only a limited
increase in the basal release of inositol could be observed
(Fig. 6a). A similar result has recently been observed for
ATP stimulation of excitatory amino acid release from
astrocytes (Mongin and Kimelberg 2002). These results
indicate that receptor activation facilitates the ability of cells
to release osmolytes under conditions of very limited
reductions in osmolarity. In this regard, it should be noted
that the ability of organic osmolytes to permeate VSOAC is
dependent upon their molecular dimensions. The minimum
diameter of the pore channel of VSOAC lies between 5.4 and
8 Å. The molecular size of the cyclical form of inositol
(7.2 · 5.9 Å) is at the upper limit, thereby resulting in a
relatively slow rate of efflux (McManus et al. 1995; Nilius
et al. 1997). In contrast, osmolytes such as glutamate,
aspartate or taurine would be expected to exit the cell more
readily. Consistent with this prediction, SH-SY5Y cells
release radiolabeled taurine more readily than inositol in
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response to mild hypo-osmotic stress, and, moreover, this
release is facilitated by mAChR activation (Fig. 6b). The
ability of mAChRs to enhance the release of organic
osmolytes from SH-SY5Y cells may constitute part of a
protective mechanism whereby cell integrity is maintained.
In this context, it is of interest to note that activation of the
same receptors on SH-SY5Y cells also protects against
metabolic insults that lead to apoptosis (De Sarno et al.
2003).
Despite the fact that the occurrence of brain swelling is of
major clinical importance, little is known regarding either the
molecular identity of VSOAC (see Nilius et al. 1997 for
review) or the identity of the cell signaling pathway(s)
involved in the activation and regulation of VSOAC. In the
present study, we demonstrate that activation of mAChRs
can modulate osmolyte release, and thus the capacity of a
neural cell to restore its volume in response to hypotonic
stress is subject to regulation by extracellular agonists. These
observations may be of interest, not only in terms of our
understanding of the basic mechanisms underlying osmolyte
release, but also may be of practical importance in terms of
the rational design of therapeutically beneficial agents.
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